Transcenta Holding (HKSE:06628) ROCE % : -34.44% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Transcenta Holding's annualized ROCE % for the quarter that ended in Dec. 2023 was -34.44%.

Transcenta Holding ROCE % Historical Data

The historical data trend for Transcenta Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding ROCE % Chart

Transcenta Holding Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-29.39

-19.03

-85.99

-19.93

-32.42

Transcenta Holding Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial				-71.09	-18.46	-21.92	-30.48	-34.44

Transcenta Holding ROCE % Calculation

Transcenta Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-488.704	/	( ( (2383.678 - 614.606)	+	(1852.095 - 606.273) )	/ 2 )
	=	-488.704	/	( (1769.072	+	1245.822)	/ 2 )
	=	-488.704	/	1507.447
	=	-32.42 %

Transcenta Holding's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-476.164	/	( ( (2111.031 - 591.35)	+	(1852.095 - 606.273) )	/ 2 )
	=	-476.164	/	( ( 1519.681	+	1245.822 )	/ 2 )
	=	-476.164	/	1382.7515
	=	-34.44 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Transcenta Holding (HKSE:06628) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Transcenta Holding ROCE % Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Transcenta Holding (HKSE:06628) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123

Website

https://www.transcenta.com

Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.

Executives

Qian Xueming	2101 Beneficial owner
Shi Xiaohong	2501 Other
Lav Corporate Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Gp Iii, L.p.	2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p.	2101 Beneficial owner
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a.	2301 Trustee
Success Link International L.p.	2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited	2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si	2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines